Vascular Biogenics Ltd. (VBLT) |
|
1.35 -0.01 (-0.74%)
|
01-21 18:20 |
|
Open: |
1.4 |
Pre. Close: |
1.36 |
|
High:
|
1.56 |
Low:
|
1.32 |
|
Volume:
|
516,744 |
Market Cap:
|
94M |
|
|
|
|
Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications in Israel and the United States. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; and VB-703 for NASH and renal fibrosis. In addition, the company is developing VB-201, a Lecinoxoid-based product candidate to treat atherosclerosis that has completed Phase II clinical; and is in Phase II exploratory trials for COVID-19, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.562 - 1.573 |
1.573 - 1.582 |
|
Low:
|
1.295 - 1.308 |
1.308 - 1.318 |
|
Close:
|
1.332 - 1.35 |
1.35 - 1.363 |
|
Technical analysis |
as of: 2022-01-21 4:31:24 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
| Target: |
Six months: 2.20  One year: 2.60 |
| Support: |
Support1: 1.32 Support2: 1.10 |
| Resistance: |
Resistance1: 1.88 Resistance2: 2.23 |
| Pivot: |
1.71 |
| Moving Average: |
MA(5): 1.50 MA(20): 1.78
MA(100): 2.15 MA(250): 2.16 |
| MACD: |
MACD(12,26): -0.17 Signal(9): -0.13 |
| Stochastic oscillator: |
%K(14,3): 4.25 %D(3): 6.17 |
| RSI: |
RSI(14): 22.24 |
| 52-week: |
High: 3.17 Low: 1.32 Change(%): -48.7 |
| Average Vol(K): |
3-Month: 225 10-Days: 332 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.VBLT has closed above bottom band by 1.9%. Bollinger Bands are 71.3% wider than normal. The large width of the bands suggest high volatility as compared to Vascular Biogenics Ltd.'s normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 21 Jan 2022
Vascular Biogenics Ltd (VBLT) Stock Decreases -14.02% This Week; Should You Buy? - InvestorsObserver
Tue, 18 Jan 2022
VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer - Yahoo Finance
Fri, 14 Jan 2022
What is Wall Street's Target Price for Vascular Biogenics Ltd (VBLT) Stock Friday? - InvestorsObserver
Thu, 06 Jan 2022
VBL Therapeutics to Present at HC Wainwright BioConnect - GlobeNewswire
Tue, 28 Dec 2021
4 REITs to Snap Up As U.S. Holiday Sales Surge - Nasdaq
Mon, 20 Dec 2021
VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
69 |
| Shares Float (M) |
46 |
|
% Held by Insiders
|
16.92 |
|
% Held by Institutions
|
19.00 |
|
Shares Short (K)
|
1,630 |
|
Shares Short P. Month (K)
|
2,220 |
Stock Financials |
|
EPS
|
-0.471 |
|
EPS Est This Year
|
-0.740 |
|
EPS Est Next Year
|
-0.780 |
|
Book Value (p.s.)
|
0.790 |
|
Profit Margin
|
|
|
Operating Margin
|
-3610.43 |
|
Return on Assets (ttm)
|
-32.2 |
|
Return on Equity (ttm)
|
-65.0 |
|
Qtrly Rev. Growth
|
3.1 |
|
Gross Profit (p.s.)
|
0.008 |
|
Sales Per Share
|
0.011 |
|
EBITDA (p.s.)
|
-0.387 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-25 |
|
Levered Free Cash Flow (M)
|
-15 |
Stock Valuations |
|
PE Ratio
|
-2.87 |
|
PEG Ratio
|
|
|
Price to Book value
|
1.71 |
|
Price to Sales
|
120.40 |
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
